FDA Panel Overwhelmingly Rejects MDMA Psychedelic as Mental Health Treatment
CCHR applauds the panel’s decision amid concerns over biased clinical trials and risks such as heart attacks, strokes, psychosis, and sexual abuse of patients during…
CCHR applauds the panel’s decision amid concerns over biased clinical trials and risks such as heart attacks, strokes, psychosis, and sexual abuse of patients during…
Mental health watchdog says adding psychedelics as approved mental health treatment will fuel more acts of drug-induced violence in the community. By Jan EastgatePresident, CCHR…
MDMA and psilocybin psychiatric research is a bad “trip” for mental health in Australia, U.S. and globally. By CCHR International The Mental Health Industry Watchdog…
Consumers and investors beware: “Bad ideas don’t get better with time.” By CCHR International The Mental Health Industry Watchdog November 8, 2021 The Citizens Commission…
By Kelly Patricia O’Meara May 28, 2015 Despite its well documented harmful and even life-threatening effects, a California psychiatrist and his partner, a therapist, have received…